BR112012027782A2 - tablete entérico - Google Patents

tablete entérico

Info

Publication number
BR112012027782A2
BR112012027782A2 BR112012027782A BR112012027782A BR112012027782A2 BR 112012027782 A2 BR112012027782 A2 BR 112012027782A2 BR 112012027782 A BR112012027782 A BR 112012027782A BR 112012027782 A BR112012027782 A BR 112012027782A BR 112012027782 A2 BR112012027782 A2 BR 112012027782A2
Authority
BR
Brazil
Prior art keywords
enteric tablet
enteric
tablet
released
intestine
Prior art date
Application number
BR112012027782A
Other languages
English (en)
Inventor
Masafumi Misaki
Masahiro Niwa
Yuki Tsushima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BR112012027782A2 publication Critical patent/BR112012027782A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

tablete entérico. é divulgado um tablete entérico que é caracterizado por ser reduzido na qualidade de talco no mesmo e por não conter nenhum componente alcalino. o tablete entérico se desintegra rapidamente uma vez liberado no intestino, de modo que o ingrediente ativo seja liberado no mesmo. consequentemente, o tablete entérico tem biodisponibilidade melhorada.
BR112012027782A 2010-04-30 2011-04-28 tablete entérico BR112012027782A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010105668 2010-04-30
PCT/JP2011/060478 WO2011136373A1 (ja) 2010-04-30 2011-04-28 腸溶性錠剤

Publications (1)

Publication Number Publication Date
BR112012027782A2 true BR112012027782A2 (pt) 2016-08-02

Family

ID=44861665

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027782A BR112012027782A2 (pt) 2010-04-30 2011-04-28 tablete entérico

Country Status (14)

Country Link
US (1) US8920840B2 (pt)
EP (1) EP2564837B1 (pt)
JP (1) JP5787881B2 (pt)
KR (1) KR20130060220A (pt)
CN (1) CN103096879B (pt)
BR (1) BR112012027782A2 (pt)
CA (1) CA2797809A1 (pt)
CL (1) CL2012003010A1 (pt)
CO (1) CO6650343A2 (pt)
ES (1) ES2723029T3 (pt)
GE (1) GEP20166487B (pt)
IL (1) IL222753A (pt)
RU (1) RU2593771C2 (pt)
WO (1) WO2011136373A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101820181B1 (ko) * 2010-04-30 2018-02-28 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
SG10201914087UA (en) 2015-07-30 2020-03-30 Takeda Pharmaceuticals Co Tablet
EP3184102A1 (en) * 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
CN109893511B (zh) * 2017-12-11 2022-07-12 湖北舒邦药业有限公司 一种地红霉素肠溶片肠溶包衣、其制备方法以及一种地红霉素肠溶片
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
EP0520119A1 (de) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
AU5310898A (en) 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2001232020A1 (en) 2000-02-09 2001-08-20 West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited Floating drug delivery composition
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
RU2311903C2 (ru) 2001-11-07 2007-12-10 Синтон Б.В. Таблетки тамзулосина
US20050025824A1 (en) 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20060210633A1 (en) 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
AU2004226838B8 (en) * 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2004096208A1 (en) 2003-04-25 2004-11-11 Mitsubishi Pharma Corporation Composition for oral administration containing alkylene dioxybenzene derivative
US20070190129A1 (en) * 2003-09-02 2007-08-16 Pfizer Inc. Sustained release dosage forms of ziprasidone
BRPI0415557A (pt) 2003-10-31 2006-12-26 Hexal Ag formulação contendo ingrediente ativo farmacêutico com revestimento
WO2005046648A1 (en) 2003-11-12 2005-05-26 Glenmark Pharmaceuticals Ltd. Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine
AU2004296877A1 (en) 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
KR100582350B1 (ko) 2004-02-17 2006-05-22 한미약품 주식회사 탐수로신 염산염의 경구투여용 조성물 및 이의 서방성과립 제제
AU2005232582B2 (en) 2004-04-01 2009-05-21 Teva Pharmaceutical Industries Ltd. Imroved formulations of 6-mercaptopurine
WO2005105036A1 (en) 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
RU2382637C2 (ru) 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
CA2574925A1 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
TW200626185A (en) 2004-12-17 2006-08-01 Bpsi Holdings Inc Enteric film coating composition containing entericpolymer micronized with detackifier
JP2008539890A (ja) * 2005-05-05 2008-11-20 プルマトリックス インコーポレイテッド 超音波式エアロゾルゼネレーター
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
JP5479909B2 (ja) 2007-11-09 2014-04-23 田辺三菱製薬株式会社 新規製剤
TW200938194A (en) 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
JP5195284B2 (ja) 2008-10-28 2013-05-08 富士レビオ株式会社 試薬容器のキャップ構造および試薬の分取方法
SI2470166T1 (sl) 2009-08-24 2014-03-31 H.Lundbeck A/S Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina

Also Published As

Publication number Publication date
CN103096879A (zh) 2013-05-08
RU2593771C2 (ru) 2016-08-10
ES2723029T3 (es) 2019-08-21
US8920840B2 (en) 2014-12-30
RU2012151315A (ru) 2014-06-10
JP5787881B2 (ja) 2015-09-30
CN103096879B (zh) 2014-12-10
EP2564837A4 (en) 2014-06-18
US20130115291A1 (en) 2013-05-09
EP2564837A1 (en) 2013-03-06
EP2564837B1 (en) 2019-01-30
IL222753A0 (en) 2012-12-31
CL2012003010A1 (es) 2013-04-01
KR20130060220A (ko) 2013-06-07
GEP20166487B (en) 2016-06-10
WO2011136373A1 (ja) 2011-11-03
CA2797809A1 (en) 2011-11-03
CO6650343A2 (es) 2013-04-15
IL222753A (en) 2017-09-28
JPWO2011136373A1 (ja) 2013-07-22

Similar Documents

Publication Publication Date Title
BR112012027794A2 (pt) tablete entérico
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
AR114143A2 (es) Formulaciones de comprimidos revestidos
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
UA109786C2 (xx) Гетероциклічні сполуки як агоністи ір-рецептора
BR112016013502A2 (pt) unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
CL2012003729A1 (es) Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.
BR112016014067A8 (pt) Implante dentário unitário endósseo
BR112012027782A2 (pt) tablete entérico
IN2015DN03984A (pt)
CL2012002786A1 (es) Comprimido sólido que se comprime directamente a partir del polvo que comprende meloxicam y uno o más exipientes; y un procedimiento de compresión directa.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
EP3626272A4 (en) MICROFIBROUS CELLULOSE, AND COMPOSITION FOR DISINTEGRATING TABLET IN ACTIVE INGREDIENT CONTENT
CL2013000089A1 (es) Tableta de desintegracion rapida en la cavidad oral que contiene particulas nucleares con acido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxilico y que estan recubiertas con dos capas.
BR112017019364A2 (pt) dispersões sólidas
PL3381457T3 (pl) Fizjologicznie czynna kompozycja zawierająca n-acetyloglukozaminę do leczenia bólów pleców
MX2017010304A (es) Composiciones farmaceuticas que comprenden meloxicam.
BR112017014295A2 (pt) composição farmacêutica.
BR112015021946A2 (pt) implante, e sistema de prótese
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
EP3303358A4 (en) Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.